Skip to content

US · IVA · BIOTECHNOLOGY

Inventiva S.A. (IVA) intrinsic value and stock valuation

$3.14as of 2026-11-21 · Mkt cap 245.36M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Inventiva S.A. DCF and intrinsic value

InvestorsCraft values IVA with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from IVA’s statements →

Inventiva S.A. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Daix, BF 21121 inventivapharma.com

How the business is doing

Fiscal 2013–2025, USD

Revenue
$4.48M+64.7% 5y CAGRd
20132025
Net income
-$-340.16M
20132025
Free cash flow
-$-101.22M
20132025
Total equity
-$-29.04M
20132025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2013–2025, USD
20252024202320222021
Revenue$4.48M$9.2M$17.5M$12.2M$4.19M
Operating income-$-130.95M-$-97.56M-$-102.71M-$-57.11M-$-52.11M
Net income-$-340.16M-$-184.21M-$-110.43M-$-54.27M-$-49.64M
EPSd-$-1.82M-$-3.54M-$-2.44M-$-1.31M-$-1.27M
Operating cash flow-$-100.98M-$-85.93M-$-81.61M-$-44.93M-$-47.63M
Capital expenditure-$-240K-$-330K-$-540K-$-560K-$-530K
Free cash flow-$-101.22M-$-86.26M-$-82.15M-$-45.49M-$-48.16M
Total assets$248.9M$119M$69.6M$116M$122M
Total debt$59.4M$54.3M$37.5M$34.5M$10.1M
Net debt-$-39.87M-$-42.23M$10.6M-$-52.22M-$-76.43M
Total equity-$-29.04M-$-106.65M-$-32.03M$45.5M$88.9M
Cash and short-term investments$99.3M$96.6M$27.3M$87.8M$86.6M
Income statement
20252024202320222021
Revenue$4.48M$9.2M$17.5M$12.2M$4.19M
Cost of revenue$2.8M$3.88M-$-20K$990K$1.02M
Gross profit$1.51M$9.2M$17.5M$17.1M$4.19M
Research and development expenses$83.6M$90.9M$110M$60.5M$48.5M
Selling, general and administrative expenses$53.9M$17.1M$15.6M$15.5M$11.5M
Other expenses-$-130K-$-1.22M-$-5.43M-$-1.8M-$-3.66M
Operating expenses$137.4M$106.8M$120.2M$74.2M$56.3M
Cost and expenses$137.4M$106.8M$120.2M$75.2M$56.3M
Interest income$2.83M$1.14M$940K$390K$60K
Interest expense$32.3M$12.2M$5.18M$710K$140K
Depreciation and amortization$2.8M$5.2M$2.6M$870K$860K
Ebitda-$-128.15M-$-166.53M-$-102.04M-$-56.29M-$-52.76M
Operating income-$-130.95M-$-97.56M-$-102.71M-$-57.11M-$-52.11M
Total other income/expenses, net-$-211.38M-$-86.34M-$-7.11M$2.82M$2.84M
Income before tax-$-342.33M-$-183.9M-$-109.82M-$-54.29M-$-49.27M
Income tax expense$20K$310K$610K-$-20K$360K
Net income-$-340.16M-$-184.21M-$-110.43M-$-54.27M-$-49.64M
Weighted average shares outstanding$186.8M$52M$45.4M$41.5M$39.2M
Weighted average diluted shares outstanding$186.8M$52M$45.4M$41.5M$39.2M
Balance sheet
20252024202320222021
Cash and short-term investments$99.3M$96.6M$27.3M$87.8M$86.6M
Net receivables$9.12M$12.2M$15.7M$280K$11.6M
Inventory$0.00$0.00$420K$370K$390K
Total current assets$243.8M$111.5M$48.2M$106.4M$115.6M
Property, plant and equipment, net$2.98M$5M$9.13M$7.39M$3.2M
Goodwill and intangible assets$180K$50K$540K$570K$770K
Long-term investments$530K$1.14M$1.43M$700K$1.75M
Total non-current assets$5.04M$7.46M$21.4M$9.62M$6.41M
Total assets$248.9M$119M$69.6M$116M$122M
Accounts payable$26M$32.9M$37.7M$19.4M$14.6M
Short-term debt$32.3M$5.87M$5.31M$5.85M$1.28M
Deferred revenue$0.00$0.00$10K$10K$0.00
Total current liabilities$77.4M$120.7M$50.2M$30.7M$22.9M
Long-term debt$27.5M$48.5M$32.2M$28.7M$8.84M
Deferred revenue, non-current$130K$110K$0.00$60K$0.00
Total non-current liabilities$200.6M$104.9M$51.4M$39.8M$10.3M
Capital lease obligations$4.81M$4.66M$6.57M$4.51M$130K
Total liabilities$277.9M$225.6M$101.6M$70.5M$33.1M
Common stock$1.93M$960K$520K$420K$410K
Retained earnings-$-354.14M-$-184.21M-$-110.43M-$-54.27M-$-49.63M
Accumulated other comprehensive income (loss)-$-204.55M-$-172.55M-$-123.99M-$-74.56M-$-26.98M
Total equity-$-29.04M-$-106.65M-$-32.03M$45.5M$88.9M
Total investments$530K$1.14M$1.5M$1.75M$1.75M
Total debt$59.4M$54.3M$37.5M$34.5M$10.1M
Net debt-$-39.87M-$-42.23M$10.6M-$-52.22M-$-76.43M
Cash flow statement
20252024202320222021
Net income-$-340.16M-$-184.21M-$-110.43M-$-54.27M-$-49.63M
Depreciation and amortization$3.22M$5.2M$2.6M$1.7M-$-1.29M
Stock-based compensation$26.8M$3.58M$3.97M$2.22M$2.09M
Change in working capital$6.42M$1.68M$17.3M$5.71M$980K
Accounts receivable$820K$2.81M-$-5.84M$3.84M-$-5.32M
Inventory$0.00$420K-$-40K$20K-$-70K
Accounts payable$2.46M$0.00$20M$3.54M$7.6M
Net cash provided by operating activities-$-100.98M-$-85.93M-$-81.61M-$-44.93M-$-47.63M
Investments in property, plant and equipment-$-240K-$-330K-$-540K-$-560K-$-530K
Acquisitions, net$0.00$0.00$0.00$40K$90K
Net cash used for investing activities-$-127.93M$8.74M-$-7.73M$8.87M-$-1.79M
Common stock issued$237.7M$57.3M$28.1M$8.83M$25.5M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$232M$145.6M$29.1M$37.3M$25.5M
Net change in cash$14.2M$69.7M-$-59.82M$180K-$-19.13M
Cash at end of period$99.3M$96.6M$26.9M$86.7M$86.6M
Operating cash flow-$-100.98M-$-85.93M-$-81.61M-$-44.93M-$-47.63M
Capital expenditure-$-240K-$-330K-$-540K-$-560K-$-530K
Free cash flow-$-101.22M-$-86.26M-$-82.15M-$-45.49M-$-48.16M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Inventiva S.A.

        Inventiva S.A. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of orally administered small molecule therapeutics. The firm primarily targets serious conditions such as non-alcoholic steatohepatitis (NASH), various forms of mucopolysaccharidoses (MPS), and other significant diseases. The company's most advanced experimental drug is Lanifibranor, which has successfully completed Phase IIb clinical trials for the treatment of NASH. Inventiva is also progressing with Odiparcil, an asset that has finished its Phase IIa clinical studies for addressing the MPS VI subtype disease. Beyond these lead candidates, Inventiva maintains a robust pipeline of earlier-stage research and development programs, notably in oncology and other therapeutic areas. The company has also established important strategic alliances, including a partnership with AbbVie focused on treatments for autoimmune diseases, and a collaboration with Boehringer Ingelheim International GmbH aimed at discovering novel therapies for idiopathic pulmonary fibrosis. Inventiva S.A. was established in 2011 and is headquartered in Daix, France.

        CEO
        Andrew Obenshain
        Employees
        73
        Beta
        0.89

        Explore

        Frequently asked questions

        What is the intrinsic value of Inventiva S.A. (IVA)?

        Inventiva S.A. (IVA) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is IVA undervalued?

        IVA trades at a price of $3.14 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.